×
OnKure Therapeutics EBIT 2020-2024 | OKUR
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
OnKure Therapeutics ebit from 2020 to 2024. Ebit can be defined as earnings before interest and taxes.
View More
OnKure Therapeutics EBIT 2020-2024 | OKUR
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
OnKure Therapeutics ebit from 2020 to 2024. Ebit can be defined as earnings before interest and taxes.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$141B
Bristol Myers Squibb (BMY)
$113.2B
Gilead Sciences (GILD)
$112B
Vertex Pharmaceuticals (VRTX)
$105.5B
CSL (CSLLY)
$84.4B
Regeneron Pharmaceuticals (REGN)
$76.6B
GSK (GSK)
$68.6B
Argenex SE (ARGX)
$39.6B
Alnylam Pharmaceuticals (ALNY)
$30.7B
BioNTech SE (BNTX)
$29.5B
Biogen (BIIB)
$21.7B
Illumina (ILMN)
$21.7B
BeiGene (ONC)
$17.3B
Moderna (MRNA)
$16.3B
Genmab (GNMSF)
$14.7B
Genmab (GMAB)
$14.7B
Incyte (INCY)
$13.6B
BioMarin Pharmaceutical (BMRN)
$12.8B
Sarepta Therapeutics (SRPT)
$11.9B
Insmed (INSM)
$11.7B
Bio-Techne Corp (TECH)
$11.6B
Exact Sciences (EXAS)
$10.5B
Exelixis (EXEL)
$10.3B
QIAGEN (QGEN)
$10.2B
Vaxcyte (PCVX)
$10.1B
Swedish Orphan Biovitrum (BIOVF)
$10.1B
Intra-Cellular Therapies (ITCI)
$10.1B
Bio-Rad Laboratories (BIO.B)
$9.5B
Repligen (RGEN)
$8.7B
Ascendis Pharma (ASND)
$7.8B